There are currently 68 active clinical trials seeking participants for Neoplasms research studies. The states with the highest number of trials for Neoplasms participants are California, Texas, Florida and New York.
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT05277051
Recruiting
This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of GSK4381562 in participants with select loco-regionally recurrent solid tumors or metastatic solid tumors where curative or standard treatment options have been exhausted.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/09/2024
Locations: GSK Investigational Site, San Francisco, California +22 locations
Conditions: Neoplasms
Register for Updates
Addressing Cancer-Related Financial Toxicity in Rural Oncology Care Settings
NCT04931251
Recruiting
The financial burden, or financial toxicity (FT), of cancer is a consequential and growing problem, particularly for rural patients. It is important to improve our understanding of how financial navigation (FN) can reduce the material, psychological, and behavioral burden of costs associated with cancer care in both rural and non-rural community settings. The purpose of this study is to conduct a financial navigation program in 5 rural and 4 non-rural oncology practices in North Carolina and eva... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: NC Basnight Cancer Hospital, Chapel Hill, North Carolina +8 locations
Conditions: Neoplasms, Carcinoma
Register for Updates
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors
NCT04446351
Recruiting
This first-time-in-human (FTIH) study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of escalating doses of GSK6097608 given as monotherapy and in combination with dostarlimab in participants with advanced solid tumors. In addition, dostarlimab will be given as monotherapy (Arm D); and in combination with belrestotug (Arm E); and with GSK6097608 + belrestotug (Arm F) in Japanese and Chinese participants. The study may asses... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/29/2023
Locations: GSK Investigational Site, Los Angeles, California +10 locations
Conditions: Neoplasms
Register for Updates
Biennial CEM in Women With a Personal History of Breast Cancer
NCT06105749
Recruiting
This is a prospective clinical trial that will examine if biennial contrast-enhanced mammography added to annual 3D mammography (tomosynthesis) substantially improves breast cancer detection with minimal increase in false-positives, in women with a personal history of breast cancer.
Gender:
Female
Ages:
Between 30 years and 79 years
Trial Updated:
10/23/2023
Locations: UPMC Magee-Womens Imaging - Bethel Park, Bethel Park, Pennsylvania +4 locations
Conditions: Breast Cancer, Breast Neoplasms, Breast Cancer Female, Neoplasms
Register for Updates
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
NCT04192344
Recruiting
This is an open-label phase 1 study to determine the safety and tolebility of oral ABSK021 in patients with advanced solid tumor as well as the Recommended Phase 2 dose (RP2D) of oral ABSK021. Preliminary antitumor activity will also be assessed.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/16/2023
Locations: Precision NextGen Oncology, Beverly Hills, California +3 locations
Conditions: Neoplasms, Tenosynovial Giant Cell Tumor
Register for Updates
Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads
NCT06018311
Recruiting
The purpose of this study is to determine the feasibility and effects of an adapted Exercising Together, a partnered resistance training program, on the physical and mental health of prostate cancer survivors and their informal caregiver. The Exercising Together program is designed to promote teamwork during supervised group exercise classes delivered remotely through videoconferencing software. The intervention period will be 3-months with a 3-month follow-up.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
09/28/2023
Locations: University of Arizona Cancer Center, Tucson, Arizona
Conditions: Neoplasms, Prostate Cancer, Exercise, Caregiver Burden
Register for Updates
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
NCT05176665
Recruiting
This study is to evaluate the safety and antitumor activity of EMB-01 in advanced/metastatic gastrointestinal cancers, including gastric cancer, hepatocellular cancer, cholangiocarcinoma and colorectal cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/27/2023
Locations: MD Anderson Cancer Center, Houston, Texas +13 locations
Conditions: Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor
Register for Updates
Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy
NCT05022667
Recruiting
This study will see if the use of near infrared autofluorescence (NIRAF) detection with a 'Parathyroid Eye (PTeye)' for identifying parathyroid glands (PGs) during total thyroidectomy (TTx) is better than surgeon's detection alone. It compares risk, benefits and outcomes in TTx patients where NIRAF detection with PTeye for parathyroid identification is either used or not used.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/27/2023
Locations: The University of Michigan, Ann Arbor, Michigan
Conditions: Thyroid Neoplasms, Thyroid Diseases, Hypoparathyroidism, Endocrine System Diseases, Endocrine Gland Neoplasms, Neoplasms by Site, Neoplasms, Head and Neck Neoplasms, Parathyroid Diseases
Register for Updates
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
NCT04075305
Recruiting
The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/25/2023
Locations: Allegheny Health Network, Pittsburgh, Pennsylvania +17 locations
Conditions: Oncology, Breast Cancer, Prostate Cancer, Gynecologic Cancer, Brain Tumor, Brain Cancer, Gynecologic Tumor, Prostate Tumor, Prostate Neoplasm, Breast Tumor, Radiation Toxicity, Quality of Life, Rectal Cancer, Rectal Tumor, Rectal Neoplasms, Lung Cancer, Lung Tumor, Lung Neoplasm, Esophageal Cancer, Esophagus Cancer, Esophageal Tumor, Esophageal Neoplasm, Esophagus Tumor, Esophagus Neoplasm, Pancreatic Cancer, Pancreatic Tumor, Pancreatic Neoplasms, Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Tumor, Tumor, Neoplasms, Bladder Cancer, Bladder Neoplasm, Liver Cancer, Liver Neoplasms, Liver Metastases, Oligometastases
Register for Updates
Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy
NCT04442724
Recruiting
The purpose of this study is to examine the usefulness of implanting small 24-K gold fiducial markers around a bladder tumor site, so that a Radiation Oncologist can identify the original tumor location at the time of radiation treatment. Other goals of the study include assessing whether a new MRI imaging technology can help with detection of bladder cancer earlier and more accurately when evidence of bladder cancer is not visible by scope.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/23/2023
Locations: Cedars-Sinai Medical Center (CSMC), Los Angeles, California +2 locations
Conditions: Bladder Cancer, Urinary Bladder Neoplasm, Urologic Neoplasms, Neoplasms, Urinary Bladder Diseases
Register for Updates
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
NCT02715284
Recruiting
This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics (PK), and pharmacodynamics (PDy) of escalating doses of dostarlimab. Dose escalation will be based on ascending weight-based dose levels (DLs... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/18/2023
Locations: GSK Investigational Site, Birmingham, Alabama +152 locations
Conditions: Neoplasms
Register for Updates
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)
NCT03739710
Recruiting
This study will compare the clinical activity of novel regimens (in combination or as single agents) to SoC in participants with relapsed/refractory advanced NSCLC. The study will be conducted in two parts. Part 1 is an open-label, optional, non-randomized part based on safety and pharmacokinetics/pharmacodynamics (PK/PD) evaluation intended to generate additional data to qualify novel regimens for the randomized study. Part 2 is a randomized, Phase II open-label part comparing the efficacy and... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/28/2023
Locations: GSK Investigational Site, Los Angeles, California +57 locations
Conditions: Neoplasms
Register for Updates